How many insider trades does FilingIQ track for TENX?

FilingIQ tracks 83 Form 4 insider transactions for TENX (TENAX THERAPEUTICS INC), covering filings from Jan 20, 2015 onwards. 2 of those were filed in the last 90 days.

Are TENX insiders net buyers or net sellers?

Across the full Form 4 history for TENX, 51 transactions (61%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TENX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TENX in?

TENAX THERAPEUTICS INC (TENX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $76.55M.

TENX insider trading

NasdaqCM Healthcare

TENAX THERAPEUTICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

61% / 1%

Market cap

$76.55M

About TENAX THERAPEUTICS INC

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Company website: www.tenaxthera.com

TENX insider activity at a glance

FilingIQ has scored 83 insider transactions for TENX since Jan 20, 2015. The most recent filing in our index is dated May 11, 2026.

Across the full history, 51 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TENX insider trades is 60.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TENX trades on FilingIQ

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for TENX?: FilingIQ tracks 83 Form 4 insider transactions for TENX (TENAX THERAPEUTICS INC), covering filings from Jan 20, 2015 onwards. 2 of those were filed in the last 90 days.
Are TENX insiders net buyers or net sellers?: Across the full Form 4 history for TENX, 51 transactions (61%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TENX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TENX in?: TENAX THERAPEUTICS INC (TENX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $76.55M.

Methodology & sources

Every TENX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.